IN THE SPECIFICATION

Amendments to the Specification:

Please amend the specification as follows:

Please replace the paragraph at page 1, lines 8-19, with the following rewritten paragraph:

It is known that IL-10, originally described as cytokine synthesis inhibitory factor, plays a role in suppressing immune and inflammatory responses in the mammalian body, by inhibiting the production of proinflammatory cytokines. A deficiency of IL-10 results in the development of a number of significant inflammatory events including ischemia-reperfusion injury, and has been implicated in autoimmune diseases such as psoriasis and pemphigus. It has been reported to be a Th2-derived cytokine that inhibits the cytokine release by Thl cells ~~(see Biorencino - et al., J. Exp. Med. 170: 3081-2095, 1989)~~ (see Fiorencino - et al., J. Exp. Med. 170: 2081-2095, 1989). Studies of the biologic activities of IL-10 *in vitro* have shown that IL-10 inhibits production of cytokines at both mRNA and protein levels by mouse Thl clones stimulated by antigen or CD3 antibody in the presence of macrophages (see, again, the above cited paper by ~~Biorencino~~ Fiorencino et al.).

Please replace the paragraph at page 14, lines 1-11, with the following rewritten paragraph:

Patients having IL-10 deficiency-associated disorders can be identified by an examination of their symptoms. The presence of the visible symptoms of psoriasis or pemphigus on a patient's skin, or the presence of symptoms of inflammatory bowel disease in a patient, are evidence of IL-10 deficiency. Such identification can also be made, or confirmed, by measurement of IL-10 and IL-10 mRNA in affected tissues of the patient, in the patient's blood and/or the patient's blood cells. IL-1 0 measurements can be conducted by methods well known to those skilled in the art - see for example the aforementioned papers of - ~~Biorencino~~ Fiorencino et al. and Kondo et al., page 1 hereof, and especially references cited

therein. Commonly, antibody measurements are used, in plasma. or tissue, as with measurements of other cytokines.

Please replace the paragraph at page 14, lines 10-25, with the following rewritten paragraph:

To obtain treated blood, the selected aliquot, in a sterile, UV-transmissive container, was treated simultaneously with a gaseous oxygen/ozone mixture and ultraviolet light at elevated temperature, using an apparatus as generally described in aforementioned US. Patent No. 4,968,483 (Mueller et al.). Specifically, 10 ml of citrated blood was transferred to a sterile, low density polyethylene vessel (more specifically, a Vasogen VC7002 Blood container) for ex vivo treatment with stressors according to the invention. Using an apparatus as described in the aforementioned Mueller patent (more specifically, a Vasogen VC7001 apparatus), the blood was heated to 42.5 ± 1°C and, at that temperature, irradiated with UV light, principally at a wavelength of 253.7 nm, while oxygen/ozone gas mixture was bubbled through the blood to provide the oxidative environment and to facilitate exposure of the blood to UV. The constitution of the gas mixture was 14.5 ± 1.0 μg ozone/ml, with the remainder of the mixture comprising medical grade oxygen. The gas mixture was bubbled through the aliquot at a rate of 240 ± 24 ml/min for a period of 3 minutes.